PIP Search Page

Displaying 61 - 80 of 970

PIPS Search Results
PIP Number	Active Substance	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Compliance outcome	Date Published Sort ascending
MHRA-101324-PIP01-23-M01 (update)	REGADENOSON	Diagnosis of myocardial perfusion disturbances	Rapiscan Rapiscan Rapiscan	Cardiovascular Diseases Diagnostic	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		03/10/2024
MHRA-101288-PIP01-23	Interleukin-2 Interleukin-1 beta, human Granulocyte colony-stimulating factor Tumor necrosis factor-alpha Interferon gamma	Treatment of squamous cell carcinoma of the head and neck (SCCHN)	Multikine	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-101007-PIP01-23	tiragolumab ATEZOLIZUMAB	Treatment of lung carcinoma (non-small cell carcinoma)	Not available at present	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-100968-PIP01-23	dirloctocogene samoparvovec	Treatment of congenital haemophilia A	Not available at present	Haematology-Hemostaseology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		03/10/2024
MHRA-101204-PIP01-23	Ravulizumab (ALXN1210)	Prevention of kidney injury in high-risk patients with chronic kidney disease undergoing cardiopulmonary bypass	Ultomiris Ultomiris Ultomiris Ultomiris	Uro-Nephrology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-100494-PIP01-22-M02 (update)	NIVOLUMAB	Treatment of malignant neoplasms of lymphoid tissue Treatment of malignant neoplasms of the central nervous system	OPDIVO OPDIVO OPDIVO OPDIVO	Oncology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		03/10/2024
MHRA-100502-PIP01-22-M02 (update)	Recombinant Influenza Hemagglutinin-strain A (H1N1 subtype) Recombinant Influenza Hemagglutinin-strain A (H3N2 subtype) Recombinant Influenza Hemagglutinin-strain B (Victoria lineage) Recombinant Influenza Hemagglutinin-strain B (Yamagata lineage)	Prevention of influenza disease	Supemtek	Vaccines	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		03/10/2024
MHRA-101127-PIP01-23	Zimberelimab	Treatment of lung cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-101126-PIP01-23	Zimberelimab	Treatment of gastric and gastroesophageal junction adenocarcinoma. Treatment of oesophageal carcinoma.		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-101400-PIP01-24	nirogacestat hydrobromide	Treatment of soft tissue sarcoma	Not yet available in the United Kingdom (Ogsiveo in the United States and European Union). Ogsiveo	Oncology	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	No		03/10/2024
MHRA-101492-PIP01-24	Recombinant Influenza Hemagglutinin-strain A (H1N1 subtype) Recombinant Influenza Hemagglutinin-strain A (H3N2 subtype) Recombinant Influenza Hemagglutinin-strain B (RIV3)	Prevention of influenza disease	Flublok	Vaccines	P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)	Yes	Full Compliance Check Granted	03/10/2024
MHRA-100086-PIP01-21-M02 (update)	UPADACITINIB	treatment of atopic dermatitis	Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq Rinvoq	Immunology -Rheumatology-Transplantation Dermatology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		03/10/2024
MHRA-100921-PIP01-23-M04 (update)	AVATROMBOPAG MALEATE	Treatment of Idiopathic Thrombocytopenia Purpura Treatment of Thrombocytopenic Purpura Secondary to Liver Disease	Doptelet Doptelet	Haematology-Hemostaseology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		03/10/2024
MHRA-101301-PIP01-23	Fusion protein consisting of relaxin and Fc domain of IgG1	Treatment of pulmonary hypertension due to left heart disease.	Not available at present	Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-101315-PIP01-23	NIVOLUMAB relatlimab	Treatment of all conditions in the category of malignant neoplasms (except nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms and melanoma)	Opdualag Opdualag Opdualag	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-101313-PIP01-23	maplirpacept	Treatment of multiple myeloma.		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-101247-PIP01-23	empasiprubart	Treatment of multifocal motor neuropathy	empasiprubart	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-101236-PIP01-23	Rilzabrutinib	Treatment of autoimmune haemolytic anaemia.		Haematology-Hemostaseology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024
MHRA-101242-PIP01-23-M01 (update)	LUMASIRAN SODIUM	Treatment of hyperoxaluria.	Oxlumo	Uro-Nephrology	PM: decision on the application for modification of an agreed paediatric investigation plan.	No		03/10/2024
MHRA-101159-PIP01-23	MK 2870- Humanised IgG1 monoclonal antibody against TROP2, conjugated to a topoisomerase I inhibitor belotecan-derivative	Treatment of lung cancer Treatment of cervical cancer Treatment of ovarian cancer Treatment of endometrial cancer Treatment of gastric cancer Treatment of breast cancer		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No		03/10/2024

Download XLSX